A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

July 31, 2023

Primary Completion Date

March 31, 2025

Study Completion Date

March 31, 2025

Conditions
Panic Disorder
Interventions
DRUG

Darigabat

Oral tablets

DRUG

Placebo

Oral tablets

Trial Locations (31)

10016

New York, New York, New York

10314

Staten Island, New York, Staten Island

11229

Brooklyn, New York, Brooklyn

11235

Brooklyn, New York, Brooklyn

14618

Rochester, New York, Rochester

19380

West Chester, Pennsylvania, West Chester

28112

Monroe, North Carolina, Monroe

30030

Decatur, Georgia, Decatur

30331

Atlanta, Georgia, Atlanta

31405

Savannah, Georgia, Savannah

32807

Orlando, Florida, Orlando

33162

North Miami Beach, Florida, North Miami Beach

33175

Miami, Florida, Miami

60123

Elgin, Illinois, Elgin

66210

Overland Park, Kansas, Overland Park

73112

Oklahoma City, Oklahoma, Oklahoma City

75115

Desoto, Texas, DeSoto

78737

Austin, Texas, Austin

84020

Draper, Utah, Draper

85012

Phoenix, Arizona, Phoenix

89102

Las Vegas, Nevada, Las Vegas

90025

Los Angeles, California, Los Angeles

90502

Torrance, California, Torrance

92056

Oceanside, California, Oceanside

92506

Riverside, California, Riverside

92868

Orange, California, Orange

94549

Lafayette, California, Lafayette

95124

San Jose, California, San Jose

98201

Everett, Washington, Everett

02131

Boston, Massachusetts, Boston

08009

Berlin, New Jersey, Berlin

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AbbVie

INDUSTRY